Keywords
Oral and maxillofacial surgery; Anaesthetic pharmacology; Drug safety; Local anaesthetic systemic toxicity; Multimodal analgesia.
Authors
Sneha S Kulkarni[1*]
Assistant Professor, Department of Chemistry, KLS Vishwanathrao Deshpande Institute of Technology, Haliyal 581329, Uttara Kannada, Karnataka.
ORCID ID: https://orcid.org/0000-0003-4753-1237
Email ID: snehakulkarni721@gmail.com

Dr. Vignan Narpati [2]
Senior Resident, Specialization: pharmacology Department Of Pharmacology , Sunderlal Patwa Medical College, Mandsaur, MP, 458001 ORCID ID: 0009-0007-4511-625X Email ID: vignan.doc@gmail.com

Dr. Pratima Singh[3]
Assitant Professor, Department of Anaesthesiology, Kanti Devi Medical College Hospital and Research Centre, Akbarpur, Chhata, Mathura Specialization: MBBS DA DNB ORCID ID: 0009-0009-5413-3718
Email ID: pratima.singh242@gmail.com

Nerella Srimannarayana[4],
Professor, Department of Mathematics,, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur(Dt.,), Andhra Pradesh, India, PIN: 522502, Specialization: Graph Theory, Special Functions and Differential Equations and Modelling of Mathematics. ORCID ID : 0000-0003-4982-5073,
Email ID : srimani72@gmail.com

Saumya Srivastava[5]
Associate Professor, Department of Physiotherapy, Nitte (Deemed to be University), Nitte Institute of Physiotherapy (NIPT), Mangalore, India.
Specialization: Orthopedic and Manual therapy ORCID ID: 0000-0001-7059-6004Email ID: saumyasri2000@nitte.edu.in

Dr Vikash Kumar Jha[6]
Senior Lecturer, Department of Oral Medicine & Radiology, KIIT University, Bhubhneswar, 751024 Specialization - Oral Medicine & Radiology ORCID ID- 0000 000307264829Email ID- jha.vikash980@gmail.com

Divyam Saxena[7]
Lecturer, Department of Pharmacology, Specialization: Pharmacology Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, India ORCID ID: https://orcid.org/0009-0002-0948-0648 Email ID: divyamsaxena321@gmail.com

Received: 10.03.2026

Accepted: 06.04.2026

DOI: 10.1922/ejprd.v34i2.1319

Pharmacological Agents and Drug Safety in Oral and Maxillofacial Surgery Anaesthesia

Abstract
Safe and effective anaesthesia is integral to modern oral and maxillofacial surgery (OMFS), particularly with the growing shift toward office-based and ambulatory procedures. This narrative review critically evaluates the pharmacological agents used in OMFS anaesthesia and examines associated safety considerations, adverse reactions, and evolving clinical strategies. Cumulative evidence on local anaesthetics, sedative-hypnotics, general anaesthetic agents, neuromuscular blockers, opioids and multimodal analgesic strategies were evaluated based on evidence accumulated through clinical trials, observational studies and professional implications. Local anaesthetic agents continue to be the basis of pain management during the perioperative period but care should be taken to prevent and treat the local anaesthetic systemic toxicity (LAST). Modern care focuses on early warning, mechanization of airways, control of seizures, and lipid emulsion. The benzodiazepines, propofol, dexmedetomidine, ketamine and inhalational agents are effective but require close titration and maintenance of respiratory and cardiovascular parameters to prevent such adverse effects as hypoventilation, hypotension, residual paralysis and hypersensitivity. Growing attention to multimodal, opioid-sparing analgesia has enhanced the level of safety in the postoperative period by decreasing the risk of respiratory depression and opioid dependence. Improved standards of monitoring especially the use of capnography in moderate and deep sedation has improved early signs of respiratory compromise in ambulatory environments. Special population considerations, comprehensive preoperative risk stratification, and structured emergency preparedness protocols are essential for minimizing preventable complications. Emerging innovations including remimazolam sedation, liposomal local anaesthetics, and ultrasound-guided techniques offer additional opportunities to enhance safety when integrated within evidence-based frameworks.

1. Introduction
Oral and maxillofacial surgery (OMFS) in the current day engages the need of safe and efficient anesthesia to carry out procedures as simple as dentoalveolar extractions, to as severe as orthognathic, trauma, oncologic, and reconstructive surgery. The shift towards office-based anesthesia and ambulatory care of the surgical care has brought about the need to be very efficient and cost effective and also access the care; however, it has also brought about the need to attain a high degree of pharmacological safety and well defined practices in the perioperative practice, etc. The clinical evidence in large scale indicates that though anesthesia induced adverse events in OMFS are rather small, respiratory and cardiovascular complications remain in the outpatient environment [1]. These findings reinforce the importance of having a well-structured monitoring system, standardized clinical pathways and constant quality improvement programs that attempt to minimize morbidity that is preventable.
The required guideline is provided by guidelines on safe practice in sedation and anesthesia. New guidelines of procedural sedation underline the

significance of the detailed preoperative assessment, which encompasses the medical history, medication review, airway, verification of fasting condition
and classification of risk based on the established classification scales, including the American Society of Anesthesiologists (ASA) Physical Status system [2]. The selection of the patients is particularly mandatory in an office-based OMFS that may not possess enough buffer of responding to unexpected complications as much as it is the case in the hospital setting. In addition, the informed consent and careful recording is also a vital part of safe and ethical practice.

Continuous physiologic monitoring throughout the time of perioperative remains of great significance to the safety of the patient. Pulse oximetry coupled with non-invasive blood pressure, electrocardiography, and capnography have become standard in OMFS because of the susceptible airway access in most of the surgical procedures where the onset of anaerobic hypoventilation, airway obstruction, and unstable hemodynamics may be observed. Capnography in particular provides an avenue of observing respiratory compromise in moderate and deep sedation that precedes the incidences of oxygen saturation. The fact that adequate standards of monitoring are maintained, and that discharge criteria are also spelled out can be listed as one of the most effective in ensuring safety provided anesthesia is delivered in the ambulatory environment.

Local anesthetic systemic toxicity (LAST) is one of the most serious comorbid drug effects in the maxillofacial practice. Though rare, LAST can progress along with the progression of initial neurologic symptoms such as circumoral numbness, tinnitus and excitement to seizures, arrhythmias, and cardiovascular collapse [3]. Newer management algorithms focus on early identification and early intervention like airway support, seizure control and immediate delivery of intravenous lipid emulsion therapy [4]. These are complemented by very sophisticated life support amenities that go hand in hand with the existing resuscitation guidelines of severe levels of toxicity or heart attack patients [5]. The response behavior in terms of preparedness and team behavior is also strengthened by the regular training in emergency simulation and easy access to resuscitation equipment.

The systemic toxicity of lidocaine and the problem of pharmacokinetic variability of local anesthesia administration has usually been given a new impulse on the recent debates [6]. Despite the fact that lidocaine is regarded to be a relatively safe drug and is at the recommended dose range; it may increase in the system during hepatic impairment, low plasma protein binding, old age, low body weight, pregnancy, polypharmacy. This inconsistency shows the necessity to establish maximum allowed doses basing on body weight and clinical conditions and aspirate before injection to minimize the risk of intravascular injection. Vasoconstrictors, such as epinephrine, will prolong the anesthetic time, and enhance hemostasis; despite the fact that they should be strictly dosed in patients with ischemic heart disease, arrhythmias, uncontrolled hypertension, or other significant cardiovascular comorbidities.

Agents that contribute to the perioperative considerations are also general agents and sedative agents. The agents that are normally used in OMFS are benzodiazepines, propofol, opioids and inhalational anesthetics which have their own pharmacodynamic properties and potential adverse effects. Respiratory depression is also a significant problem particularly in the case of opioids and sedatives being combined. Measures of multimodal analgesia will be used to reduce the use of opioids and decrease the risks. Postoperative nausea and vomiting (PONV) is still one of the most frequent complications in the ambulatory surgery that could slow the process of discharge and decrease the satisfaction level of patients. It is recommended to use prophylaxis with multimodal antiemetic regimens and risk-stratified according to the validated scoring systems to cull the PONV rate and facilitate the improved recovery regimens [7].

Neuromuscular blocking agents and airway management are also other factors that influence the safety of anesthetic care. Residual neuromuscular blockage may cause postoperative respiratory compromise, airways obstruction, and hypoxemia. Quantitative neuromuscular monitoring has been advocated in order to ensure that reversal is adequately achieved before extubation and also to minimize postoperative pulmonary complications [8]. The evaluation of the airways formally, which includes opening the mouth, the range of motion of the neck, and the distortion of the anatomy are of particular importance in maxillofacial operations. The algorithm-driven techniques of airway management improve the preparedness to difficult intubation scenarios that are common in the sphere of trauma, infection, or tumor patient cases [9]. Malignant hyperthermia is a uncommon anesthetic emergency, but it is a catastrophic scenario that must be identified, immediately provided with dantrolene iv, and observed in accordance with the standard management protocols [10].

The selection of local anesthetic agents is still evolving in dental anesthesia especially in regards to its effectiveness, diffusion properties and safety. Articaine has widely been embraced due to its good tissue penetration and action onset. Experiments conducted on the comparative basis have postulated that articaine provides good anesthesia and has equivalent safety profile compared to the traditional amide anesthetics when administered correctly [11]. Nevertheless, cautious injection technique, high-pressure intraneural injection must be prevented and recommended dose must be used to restrain neurotoxicity and other adverse outcomes.

All in all, the recent epidemiology, professional recommendation and the pharmacological research substantiate the claim that anesthesia in the OMFS has a large overall safety profile provided that evidence-based standards are maintained. The fact that infrequent complications, though potentially fatal, continue to occur, nonetheless, reflects the necessity to be on guard, make pharmacologic choices at an individual level, educate clinicians, and prepare the emergency response.

Awareness of anesthetic pharmacology, patient risks, and new standards of safety are consequently mandatory to simplify clinical practices and its safety of perioperative results and optimal standards of care that can be delivered in oral and maxillofacial surgical practice. The aims of the research are:

1. To assess the pharmacological agents used in oral and maxillofacial surgery anaesthesia and their clinical roles
2. To evaluate drug-related adverse effects and evidence-based safety management strategies in OMFS practice
3. To analyze current monitoring standards, risk stratification approaches, and emerging safety innovations to enhance patient outcomes

2. Methodology of the Review

This review was conducted using a broad narrative review approach to bring about the synthesis and critical analysis of evidence in regard to pharmacological agents used in oral and maxillofacial surgery (OMFS) anaesthesia and its safety implications. This methodology was aimed at combining various types of evidence, such as clinical trials, observational studies, pharmacokinetic studies, safety surveillance reports, and professional guidelines. Since OMFS anaesthesia is associated with local, conscious sedation, deep, and general anaesthesia, both in hospitals and offices, the literature at the heterogeneous level is available.

2.1 Design of the Review

The review was designed in the form of a comprehensive literature review of broad scope to bring together the knowledge in various areas of interest in OMFS anaesthesia. It was designed in a way that it could include randomized controlled trials, which would assess the effectiveness and safety of the drug, observational and cohort studies, which would evaluate the complications during perioperative and pharmacodynamic and pharmacokinetic studies, and consensus guidelines given by professional organizations. This method helped to compare the local anaesthetic agents, sedative-hypnotics, opioids, inhalational agents, and neuromuscular blocking drugs comparing their safety implications in special populations.

Moreover, this narrative structure enabled a review of the changing clinical practice, including multimodal analgesia, opioid-sparing interventions, enhanced recovery pathways, and better-quality monitoring in the ambulatory OMFS setting.

2.2 Sources of Literature

Different databases such as PubMed/MEDLINE, Web of Science, Cochrane library and Google scholar were used to extract literature. These databases were chosen to get high-quality research in anaesthesiology, oral and maxillofacial surgery, dental anaesthesia, pharmacology and perioperative medicine.

Besides peer-reviewed articles, professional guidelines and regulatory publications were also analyzed so as to provide the incorporation of the current safety standards. The literature provided by organizations like the American Society of Anesthesiologists (ASA) and the American Association of Oral and Maxillofacial Surgeons (AAOMS) were consulted to provide a framework on which pharmacological practices could be placed in a context of well-established clinical guidelines.

The availability of both both scholarly and institutional sources contributed to the completeness, clinical importance and scientific validity of the review.

2.3 Search Strategy

Structured search strategy was applied with the predefined keys and Boolean operators to find the relevant literature. Key search terms were oral and maxillofacial surgery anaesthesia, local anaesthetics, sedation in oral surgery, propofol, dexmedetomidine, ketamine, opioids, multimodal analgesia, local anaesthetic systemic toxicity and office-based anesthesia safety. Keywords were searched separately and in combination with operators like AND and OR to narrow down the searches. To find the other relevant studies, the reference lists of the chosen articles were screened manually.

2.4 Inclusion and Exclusion Criteria

The studies were also considered to include when they investigated the use of a pharmacological agent in OMFS anaesthesia and when they were discussing safety outcomes, adverse events, toxicity, drug interactions, or perioperative complications. Study designs that were eligible, comprised of randomized controlled trials, observational studies, meta-analyses, systematic reviews and professional guidelines.

Articles not related to dental or maxillofacial anaesthesia, those that do not discuss pharmacological safety, and articles that do not provide sufficient clarity of methodology were filtered out. Redundant publications were eliminated. The regularity of such criteria guaranteed the academic rigor, relevancy, and unity in the compilation of evidence.

3. Local Anaesthetic Agents and Vasoconstrictors

The most important type of pharmacological modality in the context of pain management during oral and maxillofacial surgery (OMFS) is local anaesthetic agents. Their action by effect is reversible blockage of sodium channels in the peripheral nerve membrane and hence inhibites the influx of sodium when depolarizing and the transmission of signals of nociceptives to the central nervous system [12]. Differentiating nerve fiber sensitivity offers an explanation as to why in clinical use a larger A-delta fibers and unmyelinated C fibers, which transmit pain, are inhibited sooner than larger motor fibers, which would result in useful analgesia using minimum level of motor dysfunction.

The most common types of local anaesthetics used in OMFS include amide-type, which has a predictable metabolism and a low rate of allergic response as compared to the esters. Lidocaine is the reference standard due to its fast onset, intermediate action and safety profile [13]. The increased lipid solubility and excellent tissue diffusion of articaine has earned it a lot of acceptance especially in infiltration anesthesia when performing dental surgeries [14]. Bupivacaine has a

longer duration of action and is useful when a long procedure is involved or a long-lasting postoperative analgesia is required but its increased cardiotoxic nature requires that the maximum dosage is adhered to. Mepivacaine has low inherent vasodilatory properties and can be used in areas where contraindicated vasoconstrictors are used. Structurally related to bupivacaine, ropivacaine is long-lasting anesthesia that has a relatively lower risk of cardiotoxicity.

Local anaesthetics rely on the pharmacokinetic profile that defines the duration of action and the onset of action. The pKa of the agent and pH of tissue have an effect on onset, whereas protein binding and lipid solubility have an effect on duration. Systemic toxicity should be avoided by computing the maximum recommended doses depending on the body weight of the patient and the total volume that has been administered. Systemic absorption is dependent on several factors which are; vascularity of the injection site, the amount of dosage administered, the administration rate, age, hepatic clearance, and cardiovascular status of the patient [15]. Sites of injecting substances of high vascularity enhance the systemic uptake and may lead to an increase in the plasma concentration, which can have an adverse effect. To extend the duration of the anesthetic time and improve an intraoperative haemostasis, vasoconstrictors are usually included in local anesthetic solutions. The most popular vasoconstrictor option is epinephrine, which can be used to stimulate the alpha-adrenergic receptors and decrease the local blood circulation, decrease the systemic absorption, and prolong the anesthetic effect [16]. Levonordefrin has the same vasoconstrictive effects but with a slightly lower level of beta- adrenergic cardiac stimulation. Vasoconstrictors additive increases visibility of the surgical field and reduce maximal plasma anesthetic levels. Yet, cardiovascular implications should be taken into consideration. Overdose of epinephrine can cause tachycardia, hypertension or arrhythmias, especially in the patients with ischemic heart diseases or untreated hypertension [17]. Some of the current recommendations include restricting epinephrine dose in cardiac patients to about 0.04 mg per administration. The drug interactions should also be placed into consideration particularly in those who are on non-selective beta blockers, tricyclic antidepressants, or monoamine oxidase inhibitors, which can enhance hypertensive responses. Figure 1 depicts that intravenous lipid emulsion therapy alleviates local anaesthetic systemic toxicity, which is accompanied by both pharmacokinetic and cardioprotective processes. Redistribution of lipophilic anesthetic molecules outside the heart and brain by the lipid sink effect, plus mitochondrial functionality and ATP replenishment by activation of intracellular signaling pathways (PI3K/Akt, eNOS).



Figure 1: Mechanisms of Intravenous Lipid Emulsion in Local Anaesthetic Systemic Toxicity [18]

The worst complication related to the use of local anaesthetics is Local Anaesthetic Systemic Toxicity (LAST). Last though rare, the onset of LAST can be followed by neurologic symptoms including circumoral numbness, tinnitus, agitation, or seizures, which later develop into cardiovascular instability and cardiac arrest cases in extreme cases [19]. Modern practice guidelines focus on the prompt identifications, airway stabilization, seizure management, and cardiovascular support, and intravenous lipid emulsion therapy as an organized resuscitation strategy. Prevention measures are the most important and they involve prudent calculation of doses, aspiration before injecting the drug to prevent intravascular injection, incremental and slow modes of injection, and constant observation of patients.

Local anaesthetic agents and vasoconstrictors will always be indispensable to OMFS practice. Their safety and efficacy must be fully understood based on the pharmacological mechanisms, pharmacokinetic properties, risk factors associated with an individual patient, and the adherence to standardized toxicity management regimes. Such agents are predictably analgesic with an excellent overall safety profile when used in established evidence-based guidelines.

4. Sedative, Hypnotic, and General Anaesthetic Agents

Oral and maxillofacial surgery (OMFS) involves the use of sedative, hypnotic and general anaesthetic agents especially in cases that involve deep sedation or general anaesthesia. The safety of their use is determined by their patency of the airways, hemodynamic stability, and the reduction of adverse reactions to drugs.

The use of neuromuscular blocking agents during general anaesthesia is often required to ease the management of airways and to offer the best conditions of surgical work. Rocuronium can be employed as the non-depolarizing neuromuscular blockade because it has a predictable onset and intermediate effect. The reversal of neuromuscular blockade has now evolved greatly due to the use of sugammadex a selective relaxant binding agent which entraps rocuronium molecules and allows neuromuscular functions to recover quickly. The incidence of anaphylaxis of sugammadex and neostigmine using comparative multicentre observational data have been studied and important safety considerations in drug use have been identified [20]. The incidence of hypersensitivity after the use of sugammadex has also been investigated on randomized controlled trials, which show that even though the cases are infrequent, allergic reactions are still clinically significant . The guidelines of current international practice put an emphasis on the quantitative monitoring of the neuromuscular condition to avoid residual paralysis and decrease the postoperative respiratory complications [21]. Moreover, reported case histories of anaphylactic shock, which is caused by sugammadex, are a supplement to the significance of early diagnosis and emergency preparedness.

In addition to the neuromuscular blockade, there are the sedative and hypnotic agents that are used extensively in OMFS. Mazezolam and other benzodiazepine anxiolytics, e.g., midazolam, offer anxiolysis and amnesia in potentiating the activity of GABA-A receptors. Nevertheless, respiratory depression, which is dose-dependent, can take place especially in combination with opioids and other sedatives. Flumazenil can counter benzodiazepine-induced oversedation but needs to be monitored further as it has the potential to precipitate resedation.

Propofol is still considered to be a backbone agent in deep sedation and general anaesthesia because of its rapid onset and recovery profile [22]. It causes hypnotic effects due to the amplification of neurotransmission of the inhibitory GABA. However, propofol has a low therapeutic index and can induce dose-related hypotension, bradycardia and respiratory suppression. It is thus required that there is continuous airway monitoring.

Table 1. Safety Considerations of Sedative, General Anaesthetic, and Neuromuscular Reversal Agents in Oral and Maxillofacial Surgery

Clinical Category	Key agents (examples)	Key Safety Risk	References
Sedation & GA drugs	Benzodiazepines, propofol, dexmedetomidine, ketamine, sevoflurane/desflurane/N_2O	Respiratory depression; hypotension/bradycardia; emergence reactions; MH risk	[24]
Reversal of neuromuscular blockade	Sugammadex vs neostigmine	Hypersensitivity/anaphylaxis (rare)	[20], [21], [23]
Neuromuscular monitoring	Quantitative monitoring	Residual paralysis	[22]

Dexmedetomidine is an alpha-2 sedative with selective alpha-2 adrenergic receptors that offers a co-operative state of sedation at low rates of respiratory depression. Nevertheless, it has sympatholytic action that is likely to cause bradycardia and hypotension especially with loading doses.

Ketamine causes dissociative anaesthesia by antagonizing NMDA receptors and offers excellent analgesia with reflexes of the airways. Sympathetic stimulation also tends to raise heart rate and blood pressure and this can be beneficial when used on a selected patient [23]. The possible adverse effects include emergence reactions, hallucinations and postoperative agitation.

The inhalational agents are sevoflurane and desflurane which are commonly used in general anaesthesia to carry out OMFS surgery that need endotracheal intubation. Nitrous oxide can be implemented as an addictive agent of anxiolysis and light analgesia in the office practice. Nevertheless, inhalational agents have the disadvantage of malignant hyperthermia among the vulnerable people who should be adequately screened and ready to handle emergency cases [24].

In general, OMFS safe usage of sedative, hypnotic, and general anaesthetic drugs is based on evidence-based drug choice, quantitative neuromuscular surveillance, cautious dose modulation, and attentive monitoring of airways and cardiovascular conditions. Hypersensitivity risk, residual paralysis, and hemodynamic instability awareness is critical to the optimal patient outcomes both in the office setting and in the hospital setting.

5. Opioid and Non-Opioid Analgesics and Multimodal Strategies

Pain management in the postoperative period in oral and maxillofacial surgery (OMFS), it is important to not only consider acute nociceptive pain but also the complications related to the procedures that could cause long-term pain. It causes sensory disturbances as well as chronic neuropathic pain, but iatrogenic inferior alveolar and lingual nerve injuries are not very common. The body of evidence in systematic review points to the relevance of early diagnosis and relevant intervention measures to lower morbidity in the long-term in cases of such nerve damage [25].

Recent clinical practice guidelines highly advocate the application of non-opioids analgesics as initial treatments of acute dental pain. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen alone or in combination show the best or similar analgesic effects as opioid-based regimens in most dentoalveolar surgeries [26]. These mediators attack peripheral inflammatory (NSAIDs through cyclooxygenase inhibition) and central analgesic (acetaminophen) pathways which are the basis of multimodal analgesia.

The practices of sedation and the analgesic planning are interrelated closely in the office-based settings of OMFS. Newer data that evaluated more recent sedative agents in the field of dentistry have evaluated the adverse events, awareness, and recovery, supporting the notion of a coordinated monitoring and risk reduction in the field of ambulatory practice [27]. It has been suggested to increase the standards of monitoring such as capnography and continuous carbon dioxide evaluation in moderate and deep sedation to provide the chance of finding out the onset of hypoventilation and respiratory compromise at a very early stage [28].

Even though opioids including fentanyl, remifentanil, and morphine continue to be effective painkillers due to their actions at μ-opioid receptors, there has been growing interest regarding the reduction of opioid exposure during perioperative care. Comparative critical reviews of opioid-free and opioid-sparing approaches indicate the possible advantages of decreasing adverse events related to opioids and still achieving sufficient analgesia [29]. Multimodal approach in postoperative pain management during oral and maxillofacial surgery must be structured and stepwise which will emphasize the non-opioid agents and minimize exposure to opioids [30]. Figure 2 shows that NSAIDS and acetaminophen are recommended as first-line therapy and short-course opioid rescuing agents in the treatment of uncontrolled pain with caution towards monitoring adverse effects as a key perioperative safety issue related to opioid therapy. Multimodal analgesia safety considerations are the possibility of bleeding related to platelet inhibition caused by NSAIDs, possible toxicity in the kidney in vulnerable patients, and the necessity of dose changes in acetaminophen in hepatic impairment. Selecting patients carefully and giving them an individual dosage is thus a crucial part of safe practice.

Altogether, modern OMFS pain management is built on the basis of multimodal, opioid-sparing management with evidence-based guidelines. Combination of non-opioid analgesics, systematic monitoring, and close observation of complications that could arise during the procedure will all help to improve patient safety and recovery. It has been shown through institutional analyses that respiratory compromise persists in the clinical environments in the postoperative care due to the lack of care and careful opioid dosing patterns [31]. This risk is of special concern in the context of OMFS, where surgical manipulation of airway anatomy can already be performed



Figure 2: Multimodal, Opioid-Sparing Analgesia Algorithm for Postoperative Pain Management in Oral and Maxillofacial Surgery

6. Drug Safety, Toxicity, and Adverse Reactions

Safety of the drugs is the core of oral and maxillofacial surgery (OMFS) anaesthesia, and it is required in office-based practice where organization and emergency readiness are the crucial matters. Guidelines of pediatric sedation focus on the selection of patients, dose in relation to weight, incessant surveillance, and recovery criteria to minimize adverse events before, during, and after the sedation process [32]. These principles highlight the general essence of standardized safety structures in any age group.

Local Anaesthetic Systemic Toxicity (LAST) is still among the most severe pharmacologic OMFS emergencies. The pathophysiology is absorption systemically or unintentionally intravascular injection of local anaesthetic which results in sodium channel blockage in the central nervous and cardiovascular systems. The neurologic signs appear in their early stages, such as circumoral numbness, tinnitus, agitation, and seizures, that can go on to develop myocardial depression, arrhythmias, hypotension, and cardiovascular collapse. Modern practice guidelines suggest the immediate airway stabilization, seizure management, cardiovascular resuscitation, and intravenous lipid emulsion therapy administration as the element of a systematic resuscitative algorithm [33].

The postoperative pain management should also be incorporated into a safety plan. Multimodal, opioid-sparing strategies of treating acute dental pain have evidence-based clinical practice guidelines to reduce opioid exposure and sustain sufficient analgesia [34]. The risks of respiratory depression and adverse effects of the medications are minimized by the rational choice of analgesic.

Basic anaesthetic standards necessitate a constant evaluation of oxygenation, ventilation, circulation, temperature during the sedation and general anaesthesia [35]. The most frequent adverse events are respiratory complications such as hypoventilation and apnea. It has been proved that capnography improves early warning of respiratory compromise in moderate sedation which is much safer than pulse oximetry [36]. The secondary causes of hypotension, bradycardia, and arrhythmias can be the use of sedatives, anaesthetic or local anaesthetic drugs, and it is necessary to monitor hemodynamics closely.

Table 2. Drug Safety Risks and Evidence-Based Prevention in OMFS Anaesthesia

Safety Domain	Key Clinical Risk	Core Prevention / Response	References
Pediatric sedation safety	Airway/respiratory events; dosing errors	Careful patient selection; weight-based dosing; continuous monitoring; discharge criteria	[32]
Local anaesthetic systemic toxicity (LAST)	Neurologic signs → cardiovascular collapse	Early recognition; airway support; seizure control; IV lipid emulsion protocol	[33]
Acute dental pain prescribing safety	Opioid adverse effects/misuse	Multimodal, opioid-sparing therapy; NSAID + acetaminophen first-line	[34]
Basic anaesthetic monitoring	Undetected hypoxia/instability	Continuous oxygenation, ventilation, circulation, temperature monitoring	[35]
Capnography during sedation	Missed hypoventilation/apnea	Capnography improves early detection of respiratory compromise	[36]
Neurocognitive effects of anaesthesia	Persistent cognitive changes (risk in vulnerable)	Judicious drug selection; dose optimization; minimize exposure	[37]
Remimazolam safety in dental sedation	Adverse events/awareness monitoring	Standardized safety protocols; outcome monitoring	[38]

The issue of possible long-term neurocognitive outcomes of being exposed to anaesthesia has also been investigated, especially in the vulnerable groups, which supports the rationale behind careful choice of drugs and dose optimization [37]. Also, the service reviews of newer sedative drugs in dental conscious sedation show the significance of universal safety measures and the observation of the results in introducing new pharmacologic drugs to practice [38].

Allergic and hypersensitivity reactions should be separated with the anxiety-related vasovagal reactions. IgE-mediated reactions to amide local anaesthetics are infrequent; nonetheless, the availability of anaphylaxis management (and immediate access to epinephrine and airway rescue equipment) is a requirement in an office-based practice. The interactions between drugs also contribute to perioperative safety issues, especially in patients using anticoagulants, antiplatelet, antihypertensives, antidepressants, or herbal supplements. Thorough preoperative evaluation and medication reconciliation is thus the key to avoiding negative outcomes.

The concept of drug safety in OMFS anaesthesia entails prompt identification of toxicity and maintaining the observed standards of monitoring, preparedness to manage the emergency care of LAST and respiratory compromise, and attentive assessment of the risk factors peculiar to the patient. The incorporation of evidence-based practice and systematic safety measures will continue to be the focus of reducing the number of adverse reactions that could be avoided in hospital and office practice.

7. Pharmacological Considerations in Special Populations and Clinical Safety Strategies

Safety of deep sedation and general anaesthesia in oral and maxillofacial surgery (OMFS) has been widely investigated especially in an office-based practice where

there is high patient turnover and procedures are generally an outpatient practice. Massive tests have shown that deep sedation and general anaesthesia can be safely practiced in the provision of dental care when carried out by duly qualified practitioners and with well-developed monitoring guidelines and emergency contingency plans [39]. These results highlight the significance of the organization of pharmacologic planning and risk prevention measures.

Modern reports on the use of office-based anaesthesia show a substantial increase in the overall safety standards, such as an improvement in patient selection criteria, a change in monitoring requirements, and a more robust emergency preparedness framework [40]. The focus is on the deep preoperative assessment, the identification of the high-risk patients, and access to resuscitative facilities. The focus of promoting avoidable complications is still on continuous quality improvement initiatives and following evidence-based sedation guidelines.

This is evidenced by the population-based data on morbidity and mortality of outpatient anaesthesia in oral and maxillofacial surgeons which show that major complications occur infrequent but not zero [41]. Neutral or undesirable outcomes have been reported to be related often with airway obstruction, lack of monitoring, or comorbidities in patients. These results support the need to have a detailed risk stratification, especially when dealing with medical-complicated patients. Figure 3 demonstrates that safe office-based anaesthesia in oral and maxillofacial surgery will proceed in a systematic way starting with thorough preoperative assessment (ASA classification, comorbidities, medication history) and risk assessment, and then proceeds through standardized intraoperative monitoring (SpO_2, blood pressure, ECG, capnography). Airway care and emergency drugs, such as lipid emulsion in the case of suspected LAST, are introduced in the case of an adverse reaction. The new methods of sedation like remimazolam are included in this monitored system with postoperative monitoring before discharge.



Figure 3. Office-Based Anaesthesia Safety Framework in OMFS

Local anaesthetic systemic toxicity (LAST) is one of the critical pharmacologic dental anaesthesia emergencies. Clinical evidence on the reversal of LAST also shows that it is successfully reversible in case of timely provision of intravenous lipid emulsion therapy and thus it is always important to identify LAST at an early stage and implement lipid rescue measures immediately in ambulatory care environments [42]. Lipid emulsion availability and knowledge of emergency algorithms by the staff are thus obligatory constituents of office-based OMFS practice.

New sedative substances were also tested regarding clinical safety. Remimazolam is an ultra-short-acting benzodiazepine that has shown good sedation profiles to midazolam in patients undergoing impacted tooth removal especially in individuals with high dental anxiety [43]. Future research also indicates successful sedation, and stable hemodynamics, minimal

respiratory degradation during outpatient third molar extraction surgeries [44]. These results imply that remimazol can be used to maximize safety margins in conscious sedation and has predictable features of recovery.

The totality of the present literature confirms the overall safety of office-based anaesthesia in OMFS in case strict monitoring, well-designed protocols, and pharmacologic preparedness are used. The constant monitoring of the morbidity data, introduction of lipid salvaging methods in LAST, and close implementation of the new sedative drugs can help to improve the situation with patient safety. The use of complex preoperative evaluation, close intraoperative care, and postoperative monitoring continue to be crucial in reducing adverse events in ambulatory or maxillofacial oral surgical units.

8. Conclusion

Anaesthesia in oral and maximillofacial surgery (OMFS) must be considered safe and effective, based on a thorough grasp of the pharmacologic principles, intense monitoring, and well-organized perioperative risk mitigation policies. Even though the current evidence confirms the existence of high overall safety profile of OMFS anaesthesia, some rare yet potentially fatal complications, including local anaesthetic systemic toxicity (LAST), respiratory depression, cardiovascular unsteadiness, and hypersensitivity reactions require constant readiness and compliance with evidence-based guidelines. Local anaesthetic agents will always be essential in the pain management process but proper dose calculation, incremental administration method and preparation in case of lipid emulsion therapy need to be considered to reduce systemic toxicity. Sedative, hypnotic and general anaesthetic drugs offer the flexibility of the depth of anaesthesia although close titration and constant airway and hemodynamic monitoring must be considered. The mechanisms of quantitative neuromuscular monitoring and systematic reversal countermeasures decrease the chances of residual paralysis and postoperative respiratory impairment. The increasing focus on multimodal, opioid-sparing analgesia is an important step forward in patient safety that reduces the negative effects of opioids and still delivers sufficient pain control. Ideas like improved monitoring capabilities especially capnography during moderate and profound sedation have enhanced early warning of respiratory degradation in ambulation. The new pharmacologic innovations and the new office-based safety systems are still developing but they need to be integrated under strict training, uniformity protocols and the quality assurance system.

References

1. Wiemer SJ, Mediratta JK, Triana RR, Card J, Rallis D, Rieck KL, et al. What is the incidence of anesthesia-related adverse events in oral and maxillofacial surgery offices? A review of 61,237 sedation cases from a large private practice consortium. *J Oral Maxillofac Surg.* 2024;82(8):895-901.
2. Practice guidelines for moderate procedural sedation and analgesia 2018. *Anesthesiology.* 2018;128(3):437-479. doi:10.1097/ALN.0000000000002043
3. Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine local anesthetic systemic toxicity checklist: 2020 version. *Reg Anesth Pain Med.* 2021;46(1):81-82.
4. Neal JM, Mulroy MF, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine checklist for treatment of local anesthetic systemic toxicity: 2012 version. *Reg Anesth Pain Med.* 2012;37(1):16-18.
5. Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, et al. 2023 American Heart Association focused update on management of patients with cardiac arrest or life-threatening toxicity due to poisoning. *Circulation.* 2023;148(16):e149-e184.
6. Schwenk ES, Sneyd JR, Wu CL. The state of local anaesthetic systemic toxicity in 2025: the emergence of lidocaine as our next challenge. *Br J Anaesth.* 2025;134(1):e1-e4.
7. Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg.* 2020;131(2):411-448.
8. Verma, P., & Krishnan, D. G. (2021). Office-Based Anesthesia in Oral and Maxillofacial Surgery-The American Model and Training. In *Oral and Maxillofacial Surgery for the Clinician* (pp. 79-93). Singapore: Springer Nature Singapore.
9. Apfelbaum JL, Hagberg CA, Connis RT, Abdelmalak BB, Agarkar M, Dutton RP, et al. 2022 ASA practice guidelines for management of the difficult airway. *Anesthesiology.* 2022;136(1):31-81.
10. Vincent MT. Malignant hyperthermia: A plan for improvement [dissertation]. Arizona: University of Arizona; 2022.
11. Martin E, Nimmo A, Lee A, Jennings E. Articaine in dentistry: an overview and meta-analysis. *BDJ Open.* 2021;7(1):27.
12. Feldman CA, Fredericks-Younger J, Desjardins PJ, Malmstrom H, Miloro M, Warburton G, et al. Nonopioid vs opioid analgesics after impacted third-molar extractions. *J Am Dent Assoc.* 2025;156(2):110-123.
13. Fredericks-Younger J, Andrews T, Lu SE, Matheson PB, Greenberg P, Ziccardi VB, et al. Analgesic differences in males and females after third molar surgery. *JAMA Netw Open.* 2025;8(11):e2542467.
14. Zhao N, Zeng J, Fan L, Wang J, Zhang C, Zou S, et al. Remimazolam-alfentanil vs propofol-alfentanil for third molar extraction. *Front Med (Lausanne).* 2022;9:950564.
15. Wang L, Zhou Y, Zhang T, Huang L, Peng W. Dexmedetomidine vs midazolam in dental implantation. *Biomed Res Int.* 2020;2020:6130162.
16. Haridoss S, Shan S, Madiraju GS, Swaminathan K, Mohan R, Asiri FYI, et al. Intranasal sedatives in pediatric dentistry: systematic review. *J Clin Med.* 2025;14(12):4038.

17. Tom J, Thikkurissy S, Agarwal R. The path to safety in dental anesthesia. *Curr Anesthesiol Rep.* 2024;14(2):318-329.
18. Liu Y, Zhang J, Yu P, Niu J, Yu S. Mechanisms and efficacy of intravenous lipid emulsion treatment for systemic toxicity from local anesthetics. *Front Med (Lausanne).* 2021;8:756866.
19. Youn S, Scheker K, Sheridan S, Hayashi C, Pickering TA, Costandi J. Does liposomal bupivacaine reduce postoperative pain following third molar extractions? *J Oral Maxillofac Surg.* 2025;83(1):45-53.
20. Orihara M, Takazawa T, Horiuchi T, Sakamoto S, Nagumo K, Tomita Y, et al. Incidence of anaphylaxis between sugammadex and neostigmine. *Br J Anaesth.* 2020;124(2):154-163.
21. Min KC, Bondiskey P, Schulz V, Woo T, Assaid C, Yu W, et al. Hypersensitivity incidence after sugammadex administration. *Br J Anaesth.* 2018;121(4):749-757.
22. Nemes R, Renew JR. Clinical practice guideline for management of neuromuscular blockade. *Curr Anesthesiol Rep.* 2020;10(2):90-98.
23. Koo BS, Lee SJ, Na HW, Kang WB, Kim SH. Suspected sugammadex-induced anaphylactic shock. *Anesth Pain Med.* 2019;14(3):294-298.
24. Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. *Miller's Anesthesia.* 8th ed. Philadelphia: Elsevier; 2014.
25. Coulthard P, Kushnerev E, Yates JM, Walsh T, Patel N, Bailey E, et al. Interventions for iatrogenic inferior alveolar and lingual nerve injury. *Cochrane Database Syst Rev.* 2014;(4):CD005293.
26. Green VG, Polk DE, Turturro MA, Moore PA, Carrasco-Labra A. Evidence-based clinical practice guidelines for acute dental pain. *Am J Emerg Med.* 2025;89:247-253.
27. Swart R, Maes SS, Cavanaugh D, Mason KP. Remimazolam pilot for office-based dental sedation. *J Clin Med.* 2023;12(23):7308.
28. Weaver J. The latest ASA mandate: CO_2 monitoring for moderate and deep sedation. *Anesth Prog.* 2011;58(3):111-112.
29. Shanthanna H, Ladha KS, Kehlet H, Joshi GP. Perioperative opioid administration: opioid-free vs opioid-sparing. *Anesthesiology.* 2020;134(4):645-659.
30. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: clinical practice guideline. *J Pain.* 2016;17(2):131-157.
31. Laporta ML, Sprung J, Weingarten TN. Respiratory depression in the post-anesthesia care unit. *Bosn J Basic Med Sci.* 2021;21(2):221-227.
32. Coté CJ, Wilson S, AAP, AAPD. Guidelines for monitoring pediatric patients before, during, and after sedation. *Pediatrics.* 2019;143(6):e20191000.
33. Neal JM, Barrington MJ, Fettiplace MR, Gitman M, Memtsoudis SG, Mörwald EE, et al. Third ASRA practice advisory on LAST. *Reg Anesth Pain Med.* 2018;43(2):113-123.
34. Green VG, Polk DE, Turturro MA, Moore PA, Carrasco-Labra A. Evidence-based clinical practice guidelines for acute dental pain. *Am J Emerg Med.* 2025;89:247-253.
35. American Society of Anesthesiologists. Standards for basic anesthetic monitoring. 2019.
36. Parker W, Estrich CG, Abt E, Carrasco-Labra A, Waugh JB, Conway A, et al. Benefits and harms of capnography during moderate sedation. *J Am Dent Assoc.* 2018;149(1):38-50.
37. Horan R, da Costa CS, Nambyiah P. The persistent effects of anaesthesia on the brain. *BJA Educ.* 2023;23(8):304-311.
38. Yeo XH, Doshi M, Clough S, Shehabi Z. Multi-site service evaluation on remimazolam for dental conscious sedation. *Br Dent J.* 2025;238(1):45-50.
39. Bennett JD, Kramer KJ, Bosack RC. How safe is deep sedation or general anesthesia while providing dental care? *J Am Dent Assoc.* 2015;146(9):705-708.
40. de Lima A, Osman BM, Shapiro FE. Safety in office-based anesthesia: updated review. *Curr Opin Anaesthesiol.* 2019;32(6):749-755.
41. Wardius E, Mobini A, Figueroa R, Mehra P. Outpatient anesthesia morbidity and mortality among OMFS. *J Oral Maxillofac Surg.* 2019;77(8):1602-1610.
42. Rhee SH, Park SH, Ryoo SH, Karm MH. Lipid emulsion therapy of local anesthetic systemic toxicity. *J Dent Anesth Pain Med.* 2019;19(4):181-189.
43. Li X, Tian M, Deng Y, She T, Li K. Remimazolam vs midazolam for impacted tooth removal. *J Oral Maxillofac Surg.* 2023;81(5):536-545.
44. Oue K, Oda A, Shimizu Y, Takahashi T, Kamio H, Sasaki U, et al. Remimazolam besilate for sedation in third molar extraction. *BMC Oral Health.* 2023;23(1):774.